Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.01 | — | — | — | — | — | — | — | — | — | — | — | 197.45 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 4.55 | 6.68 | 6.69 | 6.41 | 4.73 | 5.31 | 1.91 | 1.54 | 3.35 | 3.77 | 5.79 | 2.80 | 2.12 | 3.23 | 1.46 | 1.51 | 2.01 | 1.89 | 2.19 | 3.91 | 4.93 |
| — | +25.7% | +250.3% | +316.6% | +41.4% | +40.9% | -67.0% | -45.1% | +57.9% | +16.6% | +296.7% | +85.9% | +5.7% | +71.3% | -33.3% | -61.5% | -59.3% | -54.4% | -68.5% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | 75.95 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -118.7% | -46.5% | -33.7% | -33.0% | -26.5% | -56.6% | -21.5% | -18.1% | -19.0% | -14.1% | -32.4% | -27.0% | 0.3% | -29.1% | -17.7% | -15.1% | -14.1% | -10.8% | -4.4% | -14.2% | -9.6% |
| — | +17.8% | -56.8% | -82.7% | -39.9% | -302.0% | +33.7% | +33.0% | -7044.9% | +51.7% | -83.2% | -78.6% | +101.9% | -169.4% | -302.6% | -6.3% | -47.2% | -617.0% | +94.4% | — | — | |
| ROA | -53.2% | -15.8% | -11.9% | -13.8% | -10.6% | -23.2% | -10.4% | -9.3% | -10.2% | -7.7% | -17.2% | -14.7% | 0.1% | -15.7% | -10.5% | -9.3% | -9.1% | -7.2% | -2.9% | -9.4% | -6.7% |
| — | +32.0% | -14.5% | -49.2% | -4.0% | -200.4% | +39.5% | +37.2% | -7020.6% | +50.7% | -64.8% | -57.5% | +101.6% | -118.4% | -262.2% | +0.3% | -36.3% | -592.7% | +83.7% | +37.9% | +0.3% | |
| ROIC | -74.4% | -34.8% | -20.4% | -26.3% | -20.5% | -41.8% | -18.0% | -15.9% | -16.4% | -12.2% | -29.5% | -24.6% | -0.6% | -25.8% | -15.5% | -13.0% | -12.0% | -9.2% | -3.9% | -15.4% | -15.7% |
| — | +16.7% | -13.1% | -64.8% | -25.0% | -242.6% | +39.0% | +35.2% | -2851.1% | +52.7% | -90.5% | -89.6% | +95.4% | -179.0% | -295.3% | +15.9% | +23.1% | -267.5% | — | — | +95.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.49 | 0.48 | 0.63 | 0.49 | 0.46 | 0.70 | 0.44 | 0.38 | 0.33 | 0.29 | 0.28 | 0.36 | 0.26 | 0.32 | 0.27 | 0.22 | 0.20 | 0.18 | 0.16 | 0.15 | 0.12 |
| — | -31.6% | +44.6% | +30.4% | +39.9% | +140.4% | +54.4% | +3.9% | +24.1% | -8.9% | +5.8% | +67.0% | +34.1% | +79.3% | +67.3% | +42.4% | +65.7% | +123.1% | +100.7% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | 41.79 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.89 | 1.38 | 1.29 | 1.89 | 4.55 | 2.47 | 3.40 | 3.54 | 4.47 | 5.20 | 6.07 | 3.31 | 4.19 | 3.02 | 3.60 | 3.99 | 4.36 | 5.09 | 5.60 | 5.62 | 6.66 |
| — | -44.1% | -61.9% | -46.6% | +1.9% | -52.5% | -44.0% | +6.9% | +6.6% | +72.1% | +68.7% | -16.9% | -3.7% | -40.7% | -35.7% | -29.1% | -34.6% | -74.7% | -79.7% | -54.0% | -61.2% | |
| Quick Ratio | 1.89 | 1.38 | 1.29 | 1.89 | 4.55 | 2.47 | 3.40 | 3.54 | 4.47 | 5.20 | 6.07 | 3.31 | 4.19 | 3.02 | 3.60 | 3.99 | 4.36 | 5.09 | 5.60 | 5.62 | 6.66 |
| — | -44.1% | -61.9% | -46.6% | +1.9% | -52.5% | -44.0% | +6.9% | +6.6% | +72.1% | +68.7% | -16.9% | -3.7% | -40.7% | -35.7% | -29.1% | -34.6% | -74.7% | -79.7% | -54.0% | -61.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SANA stock.
Sana Biotechnology, Inc.'s current P/E is -3.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sana Biotechnology, Inc.'s business trajectory between earnings reports.